Breaking News Instant updates and real-time market news.

CRSP

Crispr Therapeutics

$16.75

-0.15 (-0.89%)

, NTLA

Intellia Therapeutics

$15.23

-0.88 (-5.46%)

09:51
08/03/17
08/03
09:51
08/03/17
09:51

Crispr stocks rise after scientists successfully fix disease mutation in embryo

Shares of Crispr Therapeutics are rising in early trading after a team of scientists reported that they were successful in editing the DNA in human embryos to correct a pathogenic gene mutation. The study, published online Wednesday in the journal Nature, described the correction of the heterozygous MYBPC3 mutation in human preimplantation embryos with "precise CRISPR-Cas9-based targeting accuracy and high homology-directed repair efficiency by activating an endogenous, germline-specific DNA repair response." Crispr Therapeutics (CRSP), which is a publicly traded company pursuing CRISPR treatments, is up 2.6% in early trading. Intellia Therapeutics (NTLA) and Editas Medicine (EDIT), which are also pursuing CRISPR treatments, are up 1.5% and 7.5%, respectively. Reference Link

CRSP

Crispr Therapeutics

$16.75

-0.15 (-0.89%)

NTLA

Intellia Therapeutics

$15.23

-0.88 (-5.46%)

EDIT

Editas Medicine

$15.81

-0.58 (-3.54%)

  • 15

    Aug

CRSP Crispr Therapeutics
$16.75

-0.15 (-0.89%)

07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Crispr Therapeutics initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Crispr Therapeutics (CRSP) with a Perform rating saying the company is in a weaker patent position than competitor Editas Medicine (EDIT).
07/13/17
RHCO
07/13/17
INITIATION
Target $16
RHCO
Hold
CRISPR Therapeutics initiated with a Hold at SunTrust
SunTrust analyst Peter Larson initiated CRISPR Therapeutics with a Hold and a $16 price target.
03/28/17
CHDN
03/28/17
INITIATION
Target $23.5
CHDN
Buy
CRISPR Therapeutics initiated with a Buy at Chardan
Chardan analyst Madhu Kumar initiated CRISPR Therapeutics with a Buy and a $23.50 price target saying upside from clinical leadership in CRISPR therapy offsets any potential downside from its IP exposure.
02/16/17
PIPR
02/16/17
NO CHANGE
Target $21
PIPR
Overweight
Piper's Schimmer calls CRISPR selloff 'major overreaction'
Piper Jaffray analyst Joshua Schimmer views yesterday's selloff in shares of CRISPR Therapeutics (CRSP) as a "major overreaction." The stock closed yesterday down 8%, or $1.36, to $15.90 after the patent office did not allow the patent interference with UC Berkeley versus Broad Institute over a Crispr/Cas-9 patent. Now that it's deemed patentable, CRISPR will move forward to get its own claims issued and likely move towards a second interference, Schimmer tells investors in a research note. CRISPER and Intellia Therapeutics (NTLA) are essentially litigation partners against the Broad, and now have the chance to win by knocking out Editas Medicine's (EDIT) single-guide tracr patent or by showing it was the first to invent and reduce to practice the application in eukaryotes, the analyst contends. Schimmer says he can't understand why Editas' valuation is higher than CRISPR's. He believes it should be the opposite. The analyst keeps an Overweight rating on CRISPR with a $21 price target.
NTLA Intellia Therapeutics
$15.23

-0.88 (-5.46%)

07/20/17
JEFF
07/20/17
NO CHANGE
Target $36
JEFF
Buy
Intellia should be bought for long-term opportunity, says Jefferies
After touring the company's labs, Jefferies analyst Maury Raycroft recommends buying shares of Intellia Therapeutics for the company's long-term opportunity. The analyst keeps a Buy rating on the shares with a $36 price target.
05/03/17
FBCO
05/03/17
NO CHANGE
Target $24
FBCO
Outperform
Intellia Therapeutics price target lowered to $24 from $39 at Credit Suisse
Credit Suisse analyst Alethia Young lowered her price target for Intellia Therapeutics to $24 from $39 saying that while she still likes it, big upside is likely capped until the company moves forward toward proof of concept. Young reiterates an Outperform rating on the shares.
05/31/17
JEFF
05/31/17
NO CHANGE
Target $33
JEFF
Buy
Intellia Therapeutics weakness a buying opportunity, says Jefferies
Jefferies analyst Maury Raycroft said weakness in Intellia Therapeutics shares in reaction to an article published in Nature Methods is a buying opportunity. The analyst said the story is "flawed overall" as it draws conclusions based on assessment of two experiments in mice that have different genetic makeup compared to a single control mouse, combined with other genetic variables, that may explain the article's conclusions. Raycroft said the story should not impact shares and reiterates his Buy rating and $33 price target on Intellia Therapeutics.
07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Intellia Therapeutics initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann stated Intellia Therapeutics (NTLA) with a Perform rating saying the company is currently in a weaker patent position than competitor Editas Medicine (EDIT). The analyst, however, believes Intellia has the strongest partners among the CRISPR-based companies.
EDIT Editas Medicine
$15.81

-0.58 (-3.54%)

07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Editas Medicine initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Editas Medicine (EDIT) with a Perform rating saying that while the company currently has the strongest patent position among its CRISPR-based peers, the shares are fairly valued.
07/13/17
RHCO
07/13/17
INITIATION
Target $17
RHCO
Hold
Editas Medicine initiated with a Hold at SunTrust
SunTrust analyst Peter Larson initiated Editas Medicine with a Hold and a $17 price target.

TODAY'S FREE FLY STORIES

01:55
11/22/17
11/22
01:55
11/22/17
01:55
Conference/Events
Morgan Stanley analysts hold an analyst/industry conference call »

Sales Specialist Prowse…

DE

Deere

$139.23

2.31 (1.69%)

20:25
11/21/17
11/21
20:25
11/21/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 28

    Nov

PCRX

Pacira

$42.65

0.45 (1.07%)

19:24
11/21/17
11/21
19:24
11/21/17
19:24
Recommendations
Pacira analyst commentary at BMO Capital »

October Symphony data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 14

    Dec

  • 06

    Apr

CEIX

CONSOL Energy

, ICON

Iconix Brand

$2.55

0.28 (12.33%)

19:00
11/21/17
11/21
19:00
11/21/17
19:00
Hot Stocks
S&P announces changes to S&P SmallCap 600 index »

S&P Dow Jones Indices…

CEIX

CONSOL Energy

ICON

Iconix Brand

$2.55

0.28 (12.33%)

CNX

Consol

$16.27

0.23 (1.43%)

PDFS

PDF Solutions

$15.86

0.11 (0.70%)

BBOX

Black Box

$4.15

0.55 (15.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIVO

TiVo

$17.65

0.15 (0.86%)

, CMCSA

Comcast

$36.42

0.59 (1.65%)

18:52
11/21/17
11/21
18:52
11/21/17
18:52
Recommendations
TiVo, Comcast analyst commentary at JPMorgan »

ITC ruling a…

TIVO

TiVo

$17.65

0.15 (0.86%)

CMCSA

Comcast

$36.42

0.59 (1.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GKOS

Glaukos

$25.35

-2.86 (-10.14%)

18:48
11/21/17
11/21
18:48
11/21/17
18:48
Recommendations
Glaukos analyst commentary at Piper Jaffray »

Glaukos selloff due to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$103.00

0.25 (0.24%)

, CMCSA

Comcast

$36.42

0.59 (1.65%)

18:31
11/21/17
11/21
18:31
11/21/17
18:31
Periodicals
Hulu sued for failure to offer audio service for blind subscribers, NY Post says »

Advocacy groups are suing…

DIS

Disney

$103.00

0.25 (0.24%)

CMCSA

Comcast

$36.42

0.59 (1.65%)

CMCSK

Comcast

TWX

Time Warner

$89.56

1.85 (2.11%)

FOX

21st Century Fox

$30.10

0.2 (0.67%)

FOXA

21st Century Fox

$30.88

0.22 (0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGA

Magna

$54.29

0.37 (0.69%)

18:23
11/21/17
11/21
18:23
11/21/17
18:23
Hot Stocks
Magna announces two share repurchase programs »

Magna International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 16

    Jan

PTLA

Portola Pharmaceuticals

$50.80

1.29 (2.61%)

18:23
11/21/17
11/21
18:23
11/21/17
18:23
Hot Stocks
Portola: FDA extends review period for PAS for Bevyxxa »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

PBMD

Prima BioMed

$1.65

-0.03 (-1.79%)

18:09
11/21/17
11/21
18:09
11/21/17
18:09
Hot Stocks
Prima BioMed secures European patent grant for lead product IMP321 in cancer »

Prima BioMed announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$36.70

0.39 (1.07%)

18:06
11/21/17
11/21
18:06
11/21/17
18:06
Earnings
Copart reports Q1 non-GAAP EPS 33c, consensus 27c »

Reports Q1 revenue 419.2M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 19

    Dec

PCTY

Paylocity

$47.79

-0.64 (-1.32%)

18:01
11/21/17
11/21
18:01
11/21/17
18:01
Hot Stocks
Paylocity chairman sells 736,845 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

MDC

M.D.C. Holdings

$35.10

0.91 (2.66%)

18:01
11/21/17
11/21
18:01
11/21/17
18:01
Hot Stocks
M.D.C. Holdings declares special 8% stock dividend »

M.D.C. Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDFS

PDF Solutions

$15.86

0.11 (0.70%)

, BBOX

Black Box

$4.15

0.55 (15.28%)

17:59
11/21/17
11/21
17:59
11/21/17
17:59
Hot Stocks
Breaking Hot Stocks news story on PDF Solutions, Black Box »

PDF Solutions to replace…

PDFS

PDF Solutions

$15.86

0.11 (0.70%)

BBOX

Black Box

$4.15

0.55 (15.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$22.46

0.34 (1.54%)

17:58
11/21/17
11/21
17:58
11/21/17
17:58
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. sees pressure on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CEIX

CONSOL Energy

, ICON

Iconix Brand

$2.55

0.28 (12.33%)

17:57
11/21/17
11/21
17:57
11/21/17
17:57
Hot Stocks
Breaking Hot Stocks news story on CONSOL Energy, Iconix Brand »

CONSOL Energy to replace…

CEIX

CONSOL Energy

ICON

Iconix Brand

$2.55

0.28 (12.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$22.46

0.34 (1.54%)

17:53
11/21/17
11/21
17:53
11/21/17
17:53
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. says returned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TMQ

Trilogy Metals

$0.92

-0.0211 (-2.25%)

17:53
11/21/17
11/21
17:53
11/21/17
17:53
Syndicate
Breaking Syndicate news story on Trilogy Metals »

Trilogy Metals files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRNO

Terreno Realty

$37.74

0.74 (2.00%)

17:50
11/21/17
11/21
17:50
11/21/17
17:50
Initiation
Terreno Realty initiated at National Securities »

Terreno Realty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

HPQ

HP Inc.

$22.47

0.355 (1.61%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Hot Stocks
HP Inc.: 'Stay tuned' for news on metal 3D printing »

Says plans to introduce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

THC

Tenet

$13.34

0.17 (1.29%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Initiation
Tenet initiated at William Blair »

Tenet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPNT

LifePoint

$43.85

0.65 (1.50%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Initiation
LifePoint initiated at William Blair »

LifePoint initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LHCG

LHC Group

$67.98

1.46 (2.19%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
LHC Group initiated at William Blair »

LHC Group initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

HLS

HealthSouth

$48.46

0.85 (1.79%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
HealthSouth initiated at William Blair »

HealthSouth initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$75.89

1.28 (1.72%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
HCA Healthcare initiated at William Blair »

HCA Healthcare initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.